ArticleTherapeutic advances in neurological disorders2026
Association of atherogenic index of plasma and post-stroke epilepsy in patients with ischemic stroke: a multicenter retrospective study in China.
Article in Therapeutic advances in neurological disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke epilepsy (PSE) is a common complication after ischemic stroke (IS) that worsens prognosis and quality of life. The atherogenic index of plasma (AIP) is an emerging biomarker for cardiovascular and metabolic diseases, but its link with PSE is unknown. Objective: This study aimed to evaluate the association between AIP and the risk of PSE in patients with IS. Design: A multicenter retrospective cohort study. Methods: We analyzed data from 21,459 IS patients in Southwest China (2017-2023). AIP was calculated as log10(triglycerides/high-density lipoprotein cholesterol) from baseline lipid profiles. The primary outcome was PSE occurrence within 1 year post-stroke. The relationship between AIP and PSE was assessed using multivariable logistic regression and restricted cubic spline (RCS) models, adjusting for demographic, clinical, and laboratory covariates. Subgroup and sensitivity analyses were performed to test robustness. Results: Among 21,459 participants, 936 (4.36%) developed PSE. Higher AIP levels were significantly associated with increased PSE risk. After full adjustment, each 1-standard deviation increase in AIP was associated with a 1.56-fold higher PSE risk (odds ratio = 1.56; 95% confidence interval: 1.44-1.68). Patients in the highest AIP quartile ( Conclusion: Elevated AIP is independently associated with an increased risk of PSE in IS patients, following a nonlinear dose-response pattern. AIP may serve as a valuable clinical tool for PSE risk stratification, facilitating early identification and preventive management. Prospective studies are warranted for validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.